Stocks Health care RGNX
NASDAQ · Health careREGENXBIO Inc. (RGNX)
REGENXBIO Inc. brought in $153.9M of revenue over the twelve months to September 30, 2026, down 4.6% from a year earlier. It posted a net loss of $175.2M. In fiscal 2025 capital spending exceeded operating cash flow by $126.4M. At September 30, 2026 it held $95.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about REGENXBIO Inc.
- Net worth
- REGENXBIO Inc. has a market value (market cap) of $507.6M at the latest share price, and shareholders' equity of $148M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $170.4M (+104.5% year on year), with a net loss of $193.9M. Over the 12 months to September 30, 2026: revenue $153.9M, net loss $175.2M.
- Cash flow
- In fiscal 2025 operations used $124M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- REGENXBIO Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What REGENXBIO Inc. does
REGENXBIO Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker RGNX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $170.4M | -$193.9M | -$3.76 | -$126.4M |
| 2024 | $83.3M | -$227.1M | -$4.59 | -$175.6M |
| 2023 | $90.2M | -$263.5M | -$6.02 | -$228.4M |
| 2022 | $112.7M | -$280.3M | -$6.50 | -$238.2M |
| 2021 | $470.3M | $127.8M | $2.91 | $134.7M |
| 2020 | $154.6M | -$111.3M | -$2.98 | -$80.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RGNX ranks in Health care
Latest SEC filings
What REGENXBIO Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 69% to $9.2M versus the same quarter last year; diluted EPS -$0.62 versus -$1.20.
- November 5, 2026
- October 16, 2026
- October 13, 2026Passive stake (5% or more) SCHEDULE 13G
- September 23, 2026Material agreement8-KREGENXBIO entered into a patent litigation settlement agreement with Sarepta Therapeutics and will receive a $39.0 million payment.
- August 25, 2026
- August 24, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 406% to $108M versus the same quarter last year; diluted EPS $0.43 versus -$1.38.
- August 6, 2026
- July 20, 2026Other event 8-K
Insider trades
What the people running REGENXBIO Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $949.4K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 1, 2026 | Christmas Patrick J.Chief Strategy & Legal Officer | Received as pay | 34,722 | - |
| November 1, 2026 | Pakola SteveChief Medical Officer | Received as pay | 34,722 | - |
| November 1, 2026 | Chan MitchellChief Financial Officer | Received as pay | 24,305 | - |
| November 1, 2026 | Malzahn CraigChief Technology Officer | Received as pay | 27,777 | - |
| September 1, 2026 | Chan MitchellChief Financial Officer | Shares withheld for tax | 4,902 | $45.7K |
| September 1, 2026 | Malzahn CraigChief Technology Officer | Shares withheld for tax | 234 | $2.2K |
| August 27, 2026 | Ciongoli Gregory AustinDirector | Bought | 53,407 | $499.7K |
| August 26, 2026 | Ciongoli Gregory AustinDirector | Bought | 49,196 | $449.7K |
Who owns RGNX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Redmile Group, LLC13G, passive with 2 related filers | 9.9% | August 14, 2025 |
Largest institutional holders
Insiders
15 insiders reported holding 1,923,721 shares in total, about $14.8M at the last price.
| Holder | Shares |
|---|---|
| Mills Kenneth T.Director | 495,925 |
| Simpson CurranChief Executive Officer, Director | 338,053 |
| Christmas Patrick J.Chief Strategy & Legal Officer | 240,690 |
| Pakola SteveChief Medical Officer | 240,263 |
| Chan MitchellChief Financial Officer | 147,120 |
| Ciongoli Gregory AustinDirector | 118,035 |
| Malzahn CraigChief Technology Officer | 109,737 |
| Zachary JenniferDirector | 31,871 |
| Fox Allan M.Director | 28,861 |
| Karabelas Argeris NDirector | 28,861 |
Questions about RGNX
What does REGENXBIO Inc. do?
REGENXBIO Inc. is a company in the Health care sector, listed on NASDAQ as RGNX. Its shares trade on NASDAQ under the ticker RGNX.
What is REGENXBIO Inc.'s net worth?
REGENXBIO Inc. has a market value (market cap) of $507.6M at the latest share price, and shareholders' equity of $148M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is REGENXBIO Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $175.2M on revenue of $153.9M.
How much revenue does REGENXBIO Inc. make?
Over the twelve months to September 30, 2026 REGENXBIO Inc. reported revenue of $153.9M. That is 4.6% less than a year earlier.
When did REGENXBIO Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is REGENXBIO Inc.'s next earnings report?
REGENXBIO Inc.'s next report is expected around March 4, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare RGNX with
Follow RGNX
Get an email when REGENXBIO Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values REGENXBIO Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.